Register Now & Save €300
QuintilesIMS is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS’ approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS’ broad range of healthcare information, technology and service solutions to drive new insights and approaches.
QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes.
medDigital has developed a new messaging technology called medCrowd which connects health and care teams across organizations so they can work together more effectively to give every patient the best care.
Using cutting-edge messaging technologies, health and care teams can simply invite colleagues and verified networks of advisors to join conversations and get the advice they need, when they need it.
medCrowd is a flexible technology that has many different applications. It is cloud-based and compliant for the processing of Protected Health Information (PHI), so teams can work together safely across different organizations keeping their patients' data secure.
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter.
“This was without a doubt the best and probably the most important congress/course for me in years; coming to eyeforpharma should be mandatory”
“Found the congress exceptionally informing especially at this time when the pharma industry is going through a major change in defining new commercial/operating model”
“Great event that is needed for the community”
“Complete, concrete and innovative”
“Great networking, good atmosphere - good inspiration to find ways to incorporate patients”
Complete speaker line-up • Program for all tracks & sessions • Audience breakdown
eyeforpharma is a registered company in England and Wales - Registered number 09823909. 7-9 Fashion Street, London, E1 6PX, UK. Contact Us.
Website Development by Fruitbowl Media Ltd.